|
|
| | (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Basic information |
| Product Name: | (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine | | Synonyms: | (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine;Conopharyngine pseudoindoxyl;Spiro[2H-indole-2,4'-[4H-1,6]methanoquinoline]-4'a(5'H)-carboxylic acid, 8'-ethyl-1,2',3,3',6',7',8',8'a-octahydro-5,6-dimethoxy-3-oxo-, methyl ester, (1'S,4'aS,6'R,8'R,8'aS)- (9CI) | | CAS: | 52579-71-2 | | MF: | C23H30N2O5 | | MW: | 414.5 | | EINECS: | | | Product Categories: | | | Mol File: | 52579-71-2.mol |  |
| | (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Chemical Properties |
| Boiling point | 565.1±50.0 °C(Predicted) | | density | 1.29±0.1 g/cm3(Predicted) | | pka | 7.50±0.60(Predicted) |
| | (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Usage And Synthesis |
| Description | The leaves of Tabernaemontana pachysiphon Stapf. contain this alkaloid which
has been isolated by thin layer chromatography of the alkaloidal extract. It gives
an ultraviolet spectrum consisting of absorption maxima at 217-9, 243-6 and
389-391 nm. | | References | Crooks, Robinson, 1. Pharm. Pharmacol., 25,820 (1973) |
| | (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Preparation Products And Raw materials |
|